LOGO: Allergy & Asthma Centre of Dayton    
Home | Doctors | Locations | Research | Patient Education | Contact Us |       
                       

Research

Dr. Bonnin has participated in different clinical research studies during his medical career and continues to do so. The recent studies include areas specific to asthma and sublingual allergen immunotherapy. He has made research presentations throughout the country to professional organizations including the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Currently in conjunction with
Dr. DeBrosse and Dr. Moncrief
, we are participating in a pediatric asthma study and studies in adult patients with severe asthma using biologic agents.

Dr. Bonnin has also made presentations to the International Congress of Allergology and Clinical Immunology in Sweden and the Illinois Society of Allergy and Clinical Immunology, and authored in major medical journals.

CURRENT CLINICAL STUDIES

Vestri Study: A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma.

Prospero Study: A prospective observational study to evaluate predictors of clinical effectiveness in response to omalizumab (Xolair).

Lavolta II: A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication.

PAST CLINICAL STUDIES

EXCELS Study: A five-year Phase IV study for the evaluation of Xolair’s clinical effectiveness and long-term safety.

Verse Study: A Phase IIB, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication.

COSTA Study: A Phase IIB, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and dosing regimens of quilizimab in adults with allergic asthma who are inadequately controlled on inhaled corticosteroids and a second controller.

XPORT Study: A Phase IV, multicenter, randomized, double-blind, placebo-controlled study evaluating the persistency of response with or without Xolair after long-term therapy.

Quintiles SLIT Study: A randomized, double-blind, placebo-controlled, multicenter, Phase III study of the efficacy and safety of sublingual immunotherapy administered as allergen based tablets for adult patients suffering from grass pollen rhinoconjunctivitis.

CHANGE 2 Trial: Open-Label safety/efficacy repeat exposure of study of C1 Esterase Inhibitor in the treatment of Acute Hereditary Angioedema attacks.

CHARIOT Study: Characterization of allergic asthma. A chart review in moderate to severe disease to assess asthma control, allergies, patient outcomes and treatment study.

Asmanex Study: A study of the therapeutic equivalency of MF DPI 100mcg and 200mcg inhalers in corticosteroid-dependent patients with moderate asthma.

Berinert (C1 esterace inhibitor) Study: Open-label, longitudinal registry. A prospective and retrospective data collection in the treatment of hereditary angioedema.

 

Copyright © 2018 Allergy & Asthma Centre of Dayton
Web published by
Marketing Options, LLC